Glioblastoma (GBM; synonymous with the formerly used term 'glioblastoma multiforme') is the most frequent and most aggressive malignant primary brain tumour 1,2 , and is classified as grade IV in the World Health Organization classification of tumours of the central nervous system (WHO classification of tumours of the CNS) 1 . GBM can develop from lower-grade diffuse astrocytoma (WHO grade II) and anaplastic astro cytoma (WHO grade III), and is then termed 'secondary' GBM (approximately 5% of cases). 'Primary' (de novo) GBMs are more common (approximately 95% of cases), and they typically manifest rapidly after a short clinical history and without recognizable signs of a preceding precursor lesion 3 . Diagnostic criteria for GBM, including high mitotic activity, microvascular proliferation and/or necrotic areas, are fulfilled by both primary and secondary GBM, which makes them indistinguishable by histology alone 1 . Overall, primary GBM accounts for 16% of primary brain tumours 2 . The incidence increases with age: it affects an average of 7.2 per 100,000 adults (≥19 years of age) every year, with a peak age at diagnosis between 75 and 84 years (annual incidence rate 14.6 per 100,000 individuals) 2 . Owing to the lower incidence in children, studies on paediatric high-grade gliomas (HGGs) have traditionally combined GBM, anaplastic astrocytomas and diffuse intrinsic pontine gliomas (DIPGs). Although most DIPGs histologically present as high-grade tumours and share a universally fatal outcome, they comprise tumours with varying histological grades and divergent differentiation [4][5][6][7] . Together, up to 0.8 per 100,000 children (<19 years of age) are estimated to develop HGGs each year, which makes them the most common group of malignant CNS neoplasms in this age group alongside embryonal tumours 2 . The current treatment strategy for GBM patients consists of surgery, radiotherapy and chemotherapy. Complete surgical resection of these infiltrative tumours is virtually impossible, yet gross total resection is still a positive prognostic marker. Surgery is typically not attempted for patients with DIPG because of the location of these gliomas. Concurrent adjuvant radiotherapy in combination with temozolomide represents the standard of care for patients with newly diagnosed GBM, but still less than 5% of patients survive for longer than 5 years after diagnosis 2,[8][9][10] . As no chemotherapeutic drugs have proven to be effective in the treatment of DIPG, radiation therapy alone represents the current standard regimen 11,12 . In this case, prognosis is even worse, with less than 10% of patients with DIPG surviving for more than 2 years after diagnosis 2,13 . During recent years, large-scale research effortsspearheaded by The Cancer Genome Atlas (TCGA) network and the paediatric neurooncology community - Abstract | We have extended our understanding of the molecular biology that underlies adult glioblastoma over many years. By contrast, high-grade gliomas in children and adolescents have remained a relatively under-investigated disease. The latest large-scale genomic and epigenomic profiling studies have yielded an unprecedented abundance of novel data and provided deeper insights into gliomagenesis across all age groups, which has highlighted key distinctions but also some commonalities. As we are on the verge of dissecting glioblastomas into meaningful biological subgroups, this Review summarizes the hallmark genetic alterations that are associated with distinct epigenetic features and patient characteristics in both paediatric and adult disease, and examines the complex interplay between the glioblastoma genome and epigenome.
. Diagnostic criteria for GBM, including high mitotic activity, microvascular proliferation and/or necrotic areas, are fulfilled by both primary and secondary GBM, which makes them indistinguishable by histology alone 1 . Overall, primary GBM accounts for 16% of primary brain tumours 2 . The incidence increases with age: it affects an average of 7.2 per 100,000 adults (≥19 years of age) every year, with a peak age at diagnosis between 75 and 84 years (annual incidence rate 14.6 per 100,000 individuals) 2 . Owing to the lower incidence in children, studies on paediatric high-grade gliomas (HGGs) have traditionally combined GBM, anaplastic astrocytomas and diffuse intrinsic pontine gliomas (DIPGs). Although most DIPGs histologically present as high-grade tumours and share a universally fatal outcome, they comprise tumours with varying histological grades and divergent differentiation [4] [5] [6] [7] . Together, up to 0.8 per 100,000 children (<19 years of age) are estimated to develop HGGs each year, which makes them the most common group of malignant CNS neoplasms in this age group alongside embryonal tumours 2 . The current treatment strategy for GBM patients consists of surgery, radiotherapy and chemotherapy. Complete surgical resection of these infiltrative tumours is virtually impossible, yet gross total resection is still a positive prognostic marker. Surgery is typically not attempted for patients with DIPG because of the location of these gliomas. Concurrent adjuvant radiotherapy in combination with temozolomide represents the standard of care for patients with newly diagnosed GBM, but still less than 5% of patients survive for longer than 5 years after diagnosis 2, [8] [9] [10] . As no chemotherapeutic drugs have proven to be effective in the treatment of DIPG, radiation therapy alone represents the current standard regimen 11, 12 . In this case, prognosis is even worse, with less than 10% of patients with DIPG surviving for more than 2 years after diagnosis 2, 13 . During recent years, large-scale research effortsspearheaded by The Cancer Genome Atlas (TCGA) network and the paediatric neurooncology community -1 have been directed at studying the molecular biology that underlies GBM and have generated detailed catalogues of genomic and epigenomic alterations. The new insights into gliomagenesis have triggered an avalanche of novel perceptions of the genomic and epigenomic landscape, biological subgroups and putative cells of origin of GBM, which has encouraged hopes for more effective treatment strategies in the near future. In this Review, we discuss the major recent advances in GBM molecular research, and we aim to convey important details as well as a general overview of GBM biology across all ages.
Molecular subtypes of glioblastoma
Gene expression profiling of glioblastoma. Genome-wide profiling studies using gene expression microarrays were successfully used to compare gene expression patterns in primary versus secondary GBM [14] [15] [16] [17] or adult versus paediatric GBM 18 , and to identify differentially expressed genes that could be used to distinguish different groups.
In parallel, early reports showed the usefulness of expression arrays for diagnostic assignment and prognostication within larger glioma cohorts of different grades [19] [20] [21] and within GBM cohorts only 22 . Phillips and colleagues 23 described three subclasses of HGG (termed proneural, mesenchymal and proliferative, on the basis of the functional annotation of signature genes) as being associated with different outcomes; specifically, prolonged survival of the proneural subclass. Similar subclasses of GBM were also detected in a large cohort of mixed gliomas, and data from this cohort showed a distinct gene expression cluster that was enriched for secondary GBM 24 . In partial agreement with these findings, unsupervised clustering of gene expression data from 200 adult GBM samples from the TCGA network 25, 26 identified four different molecular subtypes: proneural, neural, classical and mesenchymal. The proneural subtype was mostly characterized by abnormalities in platelet-derived growth factor receptor-α (PDGFRA) or in isocitrate dehydrogenase 1 (IDH1), whereas mutation of the epidermal growth factor receptor (EGFR) was found in the classical subgroup, and mutations in neurofibromin 1 (NF1) were common in mesenchymal tumours. This classification system has been refined by subdividing proneural GBM into glioma-CpG island methylator phenotype (G-CIMP)-positive and G-CIMP-negative GBM subsets on the basis of characteristic DNA methylation patterns that strongly correspond with IDH1 mutation status 27 (FIG. 1; discussed below). Comparing the transcriptional classification schemes of Phillips et al. 23 with those of Verhaak et al. 25 suggests that the proneural and mesenchymal signatures are the most robust and account for the greatest transcriptional variance, whereas the exact number and composition of other signatures might depend on the sample cohort compositions and experimental designs 28, 29 . The transcription factors signal transducer and activator of transcription 3 (STAT3), CCAAT/enhancer-binding protein-β (C/EBPβ) and transcriptional co-activator with PDZ-binding motif (TAZ) have been identified as epigenetic master regulators of the mesenchymal signature and might be used to predict poor clinical outcome 30, 31 . Moreover, CTNND2 (encoding catenin-δ2) and RHPN2 have recently emerged as negative and positive genetic drivers of mesenchymal transformation, respectively 32, 33 . There is also evidence of plasticity between the proneural and mesenchymal
Key points
• Glioblastoma is the most frequent and most aggressive malignant primary brain tumour and remains almost universally incurable in both children and adults.
• Comprehensive molecular profiling studies have greatly broadened our knowledge of the underlying genomic and epigenomic aberrations that are associated with glioblastoma initiation and progression.
• Genetic lesions result in disrupted epigenetic control mechanisms by altering histone modifications, DNA methylation and gene expression patterns in a large proportion of glioblastomas.
• Based on recurrent combinations of genomic and/or epigenomic features with distinct patient characteristics, glioblastomas across all ages are being divided into meaningful biological subgroups, which are likely to guide the design of future clinical trials.
• The complex interplay between the glioblastoma genome and epigenome opens the way for the development of novel innovative therapeutic strategies that are urgently needed to tackle this deadly brain tumour. subtypes in GBM 23 that might be driven by the tumour microenvironment, perhaps through microglia and the nuclear factor-κB (NF-κB) pathway 34 . The roles that the proneural and mesenchymal signatures, as well as other signatures, might have as predictors of clinical outcome remain to be clarified. The initially reported better prognosis of the proneural subclass 23, 25 was recently shown to prove true only for the G-CIMP subset, whereas non-G-CIMP proneural and mesenchymal GBM tend to show even less favourable outcomes than other GBM subtypes in the first 12 months after diagnosis 26 . Initial gene expression studies of paediatric HGG highlighted substantial differences compared with tumours from adult patients and suggested the existence of molecularly diverse subsets within paediatric cohorts 18,35-37 . Activation of a PDGFRA-driven gene expression signature has been shown in a large proportion of paediatric HGG 4, 36 , which correlates with the higher frequency of PDGFRA amplifications that occur in this age group [36] [37] [38] [39] [40] . Interestingly, one of these studies further showed shared gene expression patterns between DIPG and a proportion of midline and thalamic GBM; this indicated a closely related pathogenesis of these tumours that was later confirmed by genome sequencing studies [40] [41] [42] . Indeed, a comparison of both midline GBM and DIPG that harboured a K27M amino acid change due to a mutation in H3F3A (one of the genes that encodes histone 3.3 (H3.3)) with hemispheric GBM that had H3F3A mutations resulting in amino acid changes at G34 showed specific gene expression profiles that were distinct from each other and from tumours with wild-type H3F3A status 40, 41, 43, 44 . DNA methylation profiling of glioblastoma. Several studies have reported promoter-associated hypermethylation of specific loci in GBM, which frequently affects the expression of genes that have known tumour suppressor functions, such as cyclin-dependent kinase inhibitor 2A (CDKN2A), RB1, PTEN and TP53 , as well as previously unrecognized regulatory genes that are involved in cell proliferation (epithelial membrane protein 3 (EMP3) and PDGFB) 49, 50 , invasion (protocadherin-γ subfamily A, member 11 (PCDHGA11)) 51 or radiation sensitivity (suppressor of cytokine signalling 1 (SOCS1)) 52, 53 . Most prominently, promoter methylation of MGMT (encoding O 6 -methylguanine methyltransferase) occurs in ~45% of adult patients with GBM 26, [54] [55] [56] [57] , which leads to gene silencing and a consequently reduced proficiency for repairing DNA damage induced by alkylating agent chemotherapy [58] [59] [60] [61] . Thus, methylation at this locus has been established as a biomarker for predicting the benefit of temozolomide chemotherapy, particularly in elderly patients with GBM 56, 57, 61, 62 , although both the frequency (16-50%) [63] [64] [65] [66] and the prognostic or predictive significance of MGMT silencing in childhood HGG remain controversial 63, 66 . DNA microarray techniques have been successfully applied to study the GBM methylome in a genome-wide manner and have led to the discovery of clearly defined GBM subgroups on the basis of their global DNA methylation patterns (FIG. 1) . The first large study, with a purely adult patient cohort, reported three DNA methylation subgroups. One group was tightly associated with IDH1 ), patient age (years), telomere maintenance mechanisms (alternative lengthening of telomeres (ALT) and telomerase reverse transcriptase (TERT) promoter mutation), mutational status (H3.3 or H3.1 K27, H3.3 G34, isocitrate dehydrogenase 1 (IDH1), TP53 and neurofibromin 1 (NF1)), and copy-number aberrations of epidermal growth factor receptor (EGFR), cyclin-dependent kinase inhibitor 2A (CDKN2A), CDKN2B and platelet-derived growth factor receptor-α (PDGFRA). These associations are grouped by biological subgroup and sorted by patient age. Copy-number states, the presence of mutations and ALT positivity are represented by different colours, as indicated. The height of the bars represents an estimated percentage of cases that are positive for a specific feature. G-CIMP, glioma-CpG island methylator phenotype; RTK, receptor tyrosine kinase.
Chromothripsis
Clustered chromosomal rearrangements in one or a few chromosomes during cancer development, which are thought to occur through a one-step catastrophic genomic event.
mutations and showed concerted hypermethylation at a large number of loci, and it was therefore termed G-CIMP-positive 27 . A later study, which compared DNA methylation patterns across both paediatric and adult patients with GBM, found a similar clustering in tumours from adult patients and further identified three more distinct clusters that predominantly consisted of children and adolescents 40 . Two of these strictly corresponded with recurrent age-specific (K27 or G34) mutations in H3F3A, and another group of tumours was enriched for PDGFRA alterations; this group was termed receptor tyrosine kinase 1 (RTK-I) and consisted of patients from a more widespread age range 40 . Aberrations of PDGFRA are present in approximately 50% of G-CIMP-negative GBMs of the proneural subtype in children and adults 25, 40, 67 . Epigenetic silencing by hypermethylation of the entire genomic loci of the neural lineage markers oligodendrocyte transcription factor 1 (OLIG1) and OLIG2 was shown to be a novel and exclusive characteristic in GBM from the G34 cluster, and this finding points towards a different pathogenesis of this subgroup. These tumours also showed a considerable decrease in overall DNA methylation on a global scale 40 . This has been previously reported as a common epigenetic feature in primary GBM and was linked to genomic instability of affected regions, deficiency of the methyl group metabolism gene methylenetetrahydrofolate reductase (MTHFR) and increased proliferative activity 68 . A distinct G-CIMP-positive IDH cluster was also identified and, in agreement with previous reports, tumours from this group were found among younger adult patients, showed proneural gene expression patterns, lacked typical copy-number aberrations (CNAs) and were associated with a favourable prognosis compared with all other GBM subgroups 27, 40 , which explains the increased survival that was observed in the pro neural GBM subtype 23, 25 . The remaining G-CIMP-negative DNA methylation clusters comprised GBM samples from elderly patients, which displayed predominantly classical gene expression; combined gain of chromosome 7 and loss of chromosome 10 (7 + /10 − ); EGFR, CDKN2A and CDKN2B alterations (termed cluster #2 and RTK-II) 27, 40 ; and GBM that was enriched for mesenchymal gene expression patterns and mutations in NF1 and PTEN (termed cluster #3 and mesenchymal subtype) 27, 40 . Although mutations in H3F3A and IDH1 seem to map one-to-one with three distinct DNA methylation subclasses, recent in-depth analysis of genome-wide DNA methylation and sequencing data by the TCGA has found no similarly striking pathognomonic mutations for the additional non-G-CIMP subclasses of adult GBM 26 . This study further confirmed the notion that, despite considerable overlap, established gene expression subclasses do not directly correspond to those that are defined by DNA methylation profiling 26 -unlike DNA methylation profiling, for example, in medulloblastoma, another malignant brain tumour 69 . Whether DNA methylation profiling provides a more robust and clinically useful platform for GBM subgrouping remains to be tested, but the logistics involved are probably less error-prone than for any RNA-based analyses.
Structural variations in glioblastoma DNA CNAs are common in GBM and can affect a substantial fraction of the tumour genome 67, 70 . Assessing DNA copy number using high-resolution techniques in large collections of tumour samples has allowed the precise characterization of focal CNA target regions, and genome-wide sequencing studies are beginning to show more complex structural rearrangements and hitherto unknown fusion events. Recent data indicate that the incidence of complex chromosomal rearrangements in the context of a single catastrophic event (chromothripsis) is significantly higher in GBM (>30%) than in most other tumour types (9%), including breast, colon and lung cancer 70 . Interchromosomal, intrachromosomal (intergenic) and intragenic rearrangements can be detected in the majority (69%) of GBM samples, and these frequently (56%) co-occur with intragenic CNAs at the breakpoints 73 . The most prominent intragenic deletions in GBM target parts of the gene encoding either the extracellular domain of EGFR (exons 2-7, the deletion of which forms EGFR variant III (EGFRvIII)) or the carboxyl terminus [73] [74] [75] [76] , and these deletions are almost always associated with amplification and co-expression of the wild-type EGFR allele 26,76,77 (FIG. 2; TABLE 2) . Similarly, a fraction of PDGFRA-amplified GBM from both adults and children harbours age-specific intragenic deletion rearrangements of this kinase that result in constitutively increased activity 78, 79 . Further intragenic deletions disrupt the function of the tumour suppressor candidate gene FAS-associated factor 1 (FAF1) as a result of focal deletion of the adjacent gene, CDKN2C 73 . A breakpoint-enriched region on chromosome 12q (12q14-15), which occurs in ~5% of GBMs, was recently shown to harbour copy-number equal co-amplification of the two known GBM oncogenes, cyclin-dependent
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Double-minute chromosomes
Small circular fragments of extrachromosomal DNA that frequently harbour one or more oncogenes.
High-amplitude focal copy-number aberrations
Small fragments (typically ~3 megabases or smaller in size) of amplified or homozygously deleted DNA. Such aberrations often result in numerous copies of oncogenes or the deletion of both copies of tumour suppressor genes.
kinase 4 (CDK4) and MDM2, which were assembled into double-minute chromosomes 73, 80 . Additional fusion transcripts between genes that were included in the two amplicon segments were also observed 73 . This phenomenon was found to be mutually exclusive with CDKN2A and CDKN2B deletions and TP53 mutations, and it was associated with adverse patient survival 73 . Similarly, a number of gliomas from adult patients were previously shown to harbour double-minute chromosomes bearing amplified copies of the EGFR gene 81 (FIG. 2) . EGFR was more recently shown to be further activated by recurrent translocations in 7% of GBM samples: it was most frequently fused in-frame to septin 14 (SEPT14) or phosphoserine phosphatase (PSPH) as the 3ʹ gene segment, and it almost always occurred within amplified regions of the fusion partner genes 26, 32 . In a smaller fraction of GBMs (~3%), local inversion and in-frame fusion of the tyrosine kinase coding region of fibroblast growth factor receptor 1 (FGFR1) to the transforming acidic coiled-coil (TACC) coding domain of TACC1 (or alternatively, fusion of FGFR3 to TACC3) results in constitutive kinase activity 82, 83 . Therefore, recurrent fusion events that involve RTK-encoding genes might be a promising therapeutic target and provide a strong rationale for the inclusion of these patients in future stratified clinical trials using different RTK inhibitors.
Focal copy-number aberrations. The range of high-amplitude focal copy-number aberrations in adult GBM highlights a key role of EGFR amplifications (43% of cases), as well as CDKN2A and CDKN2B deletions (53% of cases) 26 , although these events are rarely detected in paediatric HGG (<5% and ~20% of cases, respectively) 38, 40, 72 (FIG. 1; TABLE 2). Both events are enriched in the classical (or RTK-II) and neural molecular subtypes 25 and co-occur with EGFR intragenic deletions and/or point mutations 25, 26, 76 . Known genes that are less frequently targeted by homozygous deletion in adult GBM include PTEN (10%), RB1 (3%), CDKN2C and FAF1 (3%), QKI (1.6%), NF1 (1.3%), neuronal PAS domain protein 3 (NPAS3; 1.3%) and TP53 (1%) 26 . High-level
, MET (2%) and CDK6 (1.5%) often co-occur in various combinations 26 , with common co-amplification of RTK-encoding genes in a mosaic-like pattern
. Amplifications of cyclin D2 (CCND2), CCNE1, SRY-box 2 (SOX2), MYC and MYCN are recurrent but less frequent events in adult GBM (<3% for each gene) 26 . Although most of these gains are also observed in paediatric HGG, focal amplifications of PDGFRA (14%) and MYC or MYCN (8%) are more frequent in the paediatric population 38, 40, 72, 84 . Several studies have suggested that recurrent focal amplification of PDGFRA is a key oncogenic event in DIPG 4, 37, 85 . However, with increasing amounts of molecular data on treatment-naive DIPG, the occurrence of this feature seems to be slightly lower than previously reported (<40%) and enriched in DIPG that harbours histone H3 mutations 40 (C.J., J.G., O.B., C.H., J.M. and N.J., unpublished observations). As PDGFRA amplification is more commonly observed in radiation-induced gliomas 36 , one might hypothesize a possible link between PDGFRA amplifications and prior radiotherapy -a caveat when studying post-mortem DIPG (and GBM) tissue that is obtained from autopsy cases.
Mutational spectrum of glioblastoma Advances in sequencing technology have led to the identification of increasing numbers of recurrent somatic mutations in the GBM genome of adult patients (TABLE 2) . The number of coding mutations per tumour sample is highly variable (median: ~53; range: 3-179) 26 . Frequent mutations in genes such as PTEN (29%), TP53 (29%), EGFR (20%), NF1 (9%), RB1 (8%), phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit-α (PIK3CA; 7%), phosphoinositide-3-kinase, regulatory subunit 1 (PIK3R1; 6%) and IDH1 (5%) have been reported as significant GBM signature events in earlier studies 67, 86 . The increasing number of samples with genome-wide sequencing data has now facilitated the detection of lowerfrequency events in both cancer-related genes and genes that were previously unassociated with cancer, such as TET family proteins
Figure 2 | Interplay between the glioblastoma genome and epigenome. Frequent genomic alterations in glioblastoma (GBM) that affect the epigenomic machinery are shown. Receptor tyrosine kinases (RTKs) are commonly activated by somatic mutations or structural variations (see the magnification), which leads to pyruvate kinase M2 (PKM2) nuclear translocation and to the expression of MYC and cyclin D1 (CCND1). Recurrent somatic mutations in isocitrate dehydrogenase 1 (IDH1), IDH2, histone proteins, SET domain containing 2 (SETD2) and various other chromatin-modifying proteins result in the disruption of multiple epigenetic regulatory processes by affecting histone modification, DNA methylation and chromatin remodelling. Numbers in brackets represent the estimated frequencies of alterations that occur in GBMs of adults and in childhood high-grade glioma (HGG), respectively (see 
Alternative lengthening of telomeres
(ALT). A mechanism (or mechanisms) by which 5-10% of human cancers maintain or increase the overall length of their telomeres without the need of increased telomerase activity. The exact molecular mechanism (or mechanisms) of ALT remain elusive, but they may rely on recombinationmediated elongation.
spectrin-α (SPTA1; 9%), α-thalassaemia/mental retardation syndrome X-linked (ATRX; 6%), KEL (5%), gammaaminobutyric acid A receptor, α6 (GABRA6; 4%), leucine zipper-like transcriptional regulator 1 (LZTR1; 3%), BCL6 co-repressor (BCOR; 2%), BRAF (2%), CTNND2 (2%) and QKI (2%) 26 . Some of these genes (such as LZTR1, CTNND2, QKI, BRAF and BCOR) are recurrently targeted by both CNAs and point mutations, thereby underscoring their role as new driver genes 32 . Of note, there is a nonrandom pattern of mutual exclusivities (such as PIK3R1 and PIK3CA 26, 67 ; C.J., J.G., J.M. and N.J., unpublished observations) and co-occurrences (such as IDH1, TP53 and ATRX) 26, 87, 88 , as well as multiple but overall mutually exclusive mutations in genes that are implicated in the regulation of chromatin modification 26 , which is a phenomenon that has recently been observed in various cancer types 89, 90 . On the basis of genome-wide sequencing data from 284 GBM samples generated by TCGA 26 , 46% of cases were shown to have at least one somatic mutation in a gene that was associated with DNA methylation (IDH1), histone modifications (SET domain containing 2 (SETD2), lysine-specific demethylase 6A (KDM6A), mixed lineage leukaemia 2 (MLL2), MLL3, MLL4, enhancer of zeste homologue 2 (EZH2) and histone deacetylase 2 (HDAC2)) or chromatin remodelling (ATRX, CREB-binding protein (CREBBP), chromodomain helicase DNA binding protein 5 (CHD5), CHD6, CHD7, CHD8, CHD9 and SWI/SNF-related matrix-associated, actin-dependent regulator of chromatin A2 (SMARCA2)) (FIG. 2) . (FIG. 3) . TERT promoter mutations occur at a much lower rate (3-11%) in childhood GBMs 91, 95 , which instead frequently display a loss of ATRX and an alternative lengthening of telo meres (ALT) phenotype that maintains or increases telomere length 41, 97 . Moreover, recent work has identified novel oncogenic mutations in PDGFRA in a proportion of paediatric HGGs, and this often occurs in combination with amplification of the PDGFRA locus 4, 79 . Of further note and clinical relevance, inactivating mutations in DNA mismatch repair (MMR) genes (such as MSH6) can be induced during temozolomide treatment and can evoke a GBM hypermutator phenotype, which is causally related to temozolomide resistance 67, [98] [99] [100] .
Histone mutations in childhood high-grade gliomas.
The first recurrent histone mutations in human cancer were identified by sequencing studies on a large number of samples from paediatric patients with GBM or DIPG 41, 101 . Heterozygous mutations in H3F3A result in amino acid substitutions at positions K27 or G34, and K27 was also found to be mutated in the H3.1 histone genes HIST1H3B and HIST1H3C 41,101 (C.J., J.G., O.B., C.H., J.M. and N.J., unpublished observations). These mutations directly or indirectly target important sites on the histone tail for post-translational modifications (FIG. 2) . H3 mutations occur exclusively in ~38% of childhood and young adult (age ≤30 years) HGGs 41,102 (TABLE 2) , and they occur in a mutually exclusive manner with respect to each other and to mutations in IDH1; each histone mutation also shows a strong association with distinct molecular features and with the clinical characteristics of the affected patients 5,40,42 (FIG. 1) . Mutations in H3F3A that result in amino acid changes at G34 occur in adolescents at around the age of 20 years who have disease exclusively located in hemispheric regions. A substantial number of these tumours have mutations in TP53, ATRX and (less frequently) death-domain-associated protein (DAXX) 40, 41 , and they commonly display a global pattern of DNA hypomethylation and an ALT phenotype 40 . Mutations in H3F3A that result in amino acid changes at K27 occur in 70-80% of midline GBM and DIPG in younger children 5,40,101 . The same substitutions in HIST1H3B or HIST1H3C seem to be less common (11-31%) and specific to DIPG, and to coincide with novel activating mutations in activin A receptor 1 (ACVR1; also known as ALK2), which are identified in ~20% of DIPG cases (C.J., J.G., O.B., C.H., J.M. and N.J., unpublished observations; S. J. Baker, personal communication); ACVR1 is thus a potentially druggable target in this subset. Interestingly, recent studies also detected H3F3A K27M mutations in a small fraction (<2%) of midline pilocytic astrocytomas (WHO grade I) 103, 104 ,
Box 1 | Tumour heterogeneity in glioblastoma
Intratumoural heterogeneity, which refers to the presence of multiple, epigenetically and genetically different cell subpopulations within a single tumour, might contribute to tumour growth, progression and treatment failure 180 . In glioblastoma (GBM), the previously used term 'multiforme' describes the histopathologically observed coexistence of morphologically heterogeneous areas 1 . On a molecular level, this phenomenon is represented by different area-specific chromosome aberrations [181] [182] [183] , mutations 184 and gene expression patterns 22, 185, 186 . Multiple receptor tyrosine kinase (RTK) genes -epidermal growth factor receptor (EGFR), platelet-derived growth factor receptor-α (PDGFRA) and MET -can be amplified and activated in a mutually exclusive manner in adjacent intermingled tumour cells 178, 179, 187 , and multiple EGFR-mutant alleles can commonly be expressed in a single tumour 26 . Arising from a single precursor and following an early driver event (such as loss of cyclin-dependent kinase inhibitor 2A (CDKN2A) and CDKN2B) 186, 187 , activation of different RTKs in equally proliferating subpopulations may have distinct effects on downstream signalling pathways not only within but also between and among heterogeneous subpopulations via cell-cell interactions 187 . Indeed, a paracrine mechanism has been identified by which cells that express EGFR variant III (EGFRvIII) cause wild-type EGFR-expressing cells to accelerate their proliferation through upregulation of interleukin-6 (IL-6), leukaemia inhibitory factor (LIF) and GP130, thereby potently driving growth of the entire tumour mass and maintaining tumour cell heterogeneity 188 . These observations have important implications for the effects of RTK-targeted therapies, as tumours that have mosaic driver RTK amplifications will probably require the simultaneous use of more than one targeted agent 178, 189 . Furthermore, the effect of sampling bias over space and time is an important diagnostic consideration, particularly in the era of targeted therapy 186 . Tumour heterogeneity in GBM may also arise from clonal evolution; that is, through the expansion and acquisition of mutations during tumour progression that promote genetic variability 190 . This concept may be linked with the hierarchical cancer stem cell model, which postulates a small subpopulation of stem-like cells that give rise to a tumour and are maintained through their capability to self-renew and to produce diverse daughter cells that populate the tumour bulk 191 . (FIG. 1) . Interestingly, mutations at K27 seem to confer a dismal prognosis 5,40 , whereas G34 mutations might be associated with slightly prolonged overall survival 40 . However, these initial observations will have to be tested in larger, prospective patient cohorts.
A gain-of-function K27M mutation in H3.3 or H3.1 leads to global downregulation of the repressive histone mark histone H3 lysine 27 trimethylation (H3K27me3) Figure 3 | Telomere maintenance mechanisms in glioblastoma. Maintenance of telomere length occurs by different mechanisms in glioblastoma (GBM). Alternative lengthening of telomeres (ALT), which is thought to be mediated by homologous recombination, is more prevalent in the paediatric setting (a). Although mutations in α-thalassaemia/mental retardation syndrome X-linked (ATRX) or death-domain-associated protein (DAXX; which mediate incorporation of histone H3.3 into pericentromeric and subtelomeric regions (indicated by dashed arrows)) are known to promote ALT, the contribution of p53 loss, H3.3 mutations and/or subtelomeric DNA hypomethylation (such as in GBMs that harbour H3.3 G34R or G34V mutations) needs further elucidation. In normal cells (b), the chromosome ends are protected from undergoing non-homologous end-joining or homologous recombination by forming a telomere loop (T-Loop) structure. Telomere length in adult GBM (c) in the presence of functional p53 is mostly maintained by upregulated telomerase reverse transcriptase (TERT) expression (dashed arrows) as a consequence of TERT promoter hotspot mutations (for example, C228T or C250T). TERC, telomerase RNA component.
Polycomb repressive complex 2
(PRC2). One of two classes of Polycomb-group proteins. PRC2 has methyltransferase activity and primarily trimethylates histone H3 on lysine 27 (that is, H3K27me3), which is a mark of transcriptionally silent chromatin.
through inhibition of the Polycomb repressive complex 2 (PRC2) 44, [105] [106] [107] . K27M-mutant H3.3 was shown to aberrantly bind to PRC2 and interfere with the enzymatic activity of EZH2 -the catalytic subunit of PRC2 that establishes the H3K27me3 mark -possibly as a result of methionine mimicking the structure of monomethyl lysine 106 . Consequent loss of repressive PRC2 activity reflected by reduced levels of H3K27me3 in combination with DNA hypomethylation has therefore been proposed as the main driver of gliomagenesis in K27M-mutant HGG 44, 106 (FIG. 2) .
In a similar manner, G34R-mutant and G34V-mutant H3.3 can interfere with the regulatory H3K36me3 modification 43, 106 . Genome-wide mapping of H3K36me3 in a G34V-mutant GBM cell line identified MYCN as one of the genes that was most strongly enriched for H3K36me3 marks, with increased RNA polymerase II binding and transcriptional upregulation of this locus in G34V-mutant cells 43 . Therefore, in addition to MYCN focal amplification, H3.3 G34 mutations may be an alternative mechanism to overexpress MYCN, which was recently shown to drive glioma formation in neural stem cells (NSCs) in vivo 108 , and could potentially be targeted by bromodomain inhibition 109 . H3K36me3 is further disrupted in children and young adults by mutations in the H3K36 trimethyltransferase SETD2, which are mutually exclusive with H3F3A G34 mutations 110 (FIG. 2) . Besides its role in transcriptional elongation 106 , H3K36me3 was found to be important as a recruitment platform for MMR proteins 111 . Depletion of SETD2 and therefore H3K36me3 levels in HeLa cells leads to an increased spontaneous mutation frequency and chromosomal instability 111 . In agreement with this, altered histone modifications in subtelomeric regions have been suggested to contribute to deregulated telomere length, which also results in chromosomal instability. This is reflected by a particularly high number of paediatric GBMs that show ALT 41 (FIG. 3) . Although genetic hits in ATRX and DAXX (both essential components for H3.3 incorporation at pericentromeric heterochromatin and at telomeres) are known to promote the ALT phenotype, the contribution of mutant p53 (REF. 112 ), histone modifications and subtelomeric DNA hypomethylation to GBM development needs further investigation.
IDH mutations in glioblastomas of young adults.
In the early stages of the next-generation sequencing era, the first genome-wide exon sequencing effort for glioma identified heterozygous hotspot mutations at codon 132 (most commonly R132H) in IDH1 in 12% of GBM 86 . Today, mutations in IDH1 (and to a lesser extent in IDH2) are commonly established as a hallmark molecular feature of secondary GBM in young adults (age 25-45 years; being present in ~70% of secondary GBM, compared with <5% in primary GBM) [113] [114] [115] [116] who have predominant localization of GBM in the frontal and temporal lobes 117 . Therefore, the small number of IDH-mutant primary GBMs may have rapidly progressed from clinically undiagnosed lower-grade astrocytomas. Mutations in the IDH genes are thought to cause G-CIMP within the proneural GBM subgroup 23,25,27,40,118 (FIG. 1) . The role of mutations in IDH genes in gliomas with respect to molecular pathogenesis and to clinical implications has recently been reviewed in detail 119, 120 . IDH mutations seem to require cooperating mutations in TP53 and ATRX 87, 88 , and possibly in SETD2 (REF. 110 ), and they are less frequently detected in GBMs with classical RTK pathway alterations 40, 67, 121 . Besides being a powerful diagnostic marker 122 , IDH-mutant GBMs have a relatively favourable clinical outcome compared with their non-mutated counterparts 26, 123 . The main mechanism by which mutant IDH contributes to the pathogenesis of GBM is ascribed to the neomorphic enzymatic activity of mutant IDH proteins, which produce large amounts of the r enantiomer of 2-hydroxyglutarate ((r)-2-HG; a putative oncometabolite) from 2-oxoglutarate (2-OG; also known as α-ketoglutarate) 124, 125 . (r)-2-HG has been shown to inhibit various 2-OG-dependent dioxygenases, including key epigenetic regulators such as the DNA demethylating enzymes of the TET 126 or Jumonji domain families 127, 128 (FIG. 2) . Hence, the methylome of IDH-mutant GBM is dominated by widespread DNA hypermethylation at gene promoters (G-CIMP) 118 , irrespective of patient age 40 . The interaction of TET methylcytosine dioxygenase 2 (TET2) with particular transcription factors, such as EBF1, might result in specific rather than random gene promoter hypermethylation 129 . Although there is a strong association of IDH mutation with G-CIMP, early passage neurosphere cultures from IDH-wild-type GBM can show a G-CIMP-like phenotype, which suggests the occurrence of intratumoural heterogeneity and/or the involvement of other, as-yet-unknown factors 34 .
The cells of origin of glioblastoma
Although multiple genetic and epigenetic alterations are known to initiate or promote gliomagenesis, the identity of the cell of origin that acquires the first tumourpromoting mutation remains elusive. Several cell types -including NSCs 130, 131 , more differentiated progeny, such as oligodendrocyte precursor cells (OPCs) 132, 133 , or cells of the astrocytic lineage -have been suggested as putative glioma-initiating cells. Indeed, all of these cell types can give rise to glioma if they are genetically manipulated
. Interestingly, malignant transformation does not seem to be limited to undifferentiated cell types -transformation of mature neurons or astrocytes by depletion of Nf1 and Trp53 has also been shown to generate malignant gliomas in vivo 134 . Various pieces of evidence, including differences in tumour location, patient age, mutational spectrum or expression of neuronal lineage markers, have led to growing speculation that in addition to acquiring distinct genetic events, at least some of the GBM subgroups described above have unique cellular origins. This hypothesis might especially prove true for the tight correlations between molecular and clinical characteristics that occur in DIPG and midline GBM, which possibly originate from recently identified pontine precursor-like cells 135 .
It is widely thought that IDH1-mutant GBM might represent a distinct disease entity that probably arises from a different cellular origin compared with GBM in which IDH is not mutated 136 . Based on a current model, mutations of IDH1 are an early event in gliomagenesis, which prime quiescent neural progenitor cells for additional tumour-promoting genetic hits such as TP53 mutations or 1p and 19q co-deletions, leading to the manifestation of WHO grade II or grade III gliomas. Subsequent malignant transformation into grade IV GBM is mediated by additional key genomic alterations (such as RTK pathway activation or PTEN mutations) 136 . This stepwise progression of secondary, IDH1-mutant GBM, with preservation of a proneural expression pattern, substantially differs from de novo GBM, which seems to originate as the result of genetic hits in a distinct cell population that more closely resembles NSCs 136 . Lineage-tracing experiments have indicated that OPCs can be considered as cells of origin for Nf1-mutant and Trp53-mutant GBMs, although identical genetic hits can also give rise to glioma when they are introduced into NSCs 132 . In a pre-malignant state, in vivo proliferation of Nf1;Trp53-mutant cells was found to be dramatically increased only in the OPC lineage and not in NSCs or in progeny lineages of astrocytes, neurons or oligodendrocytes. Fascinatingly, the direct introduction of Nf1 and Trp53 mutations into OPCs led to the generation of gliomas that molecularly and histologically resembled tumours that initiated from NSCs, with transcriptomes of both models corresponding well with the proneural subtype 132 . Assuming that tumours partially retain the gene expression signature of their cellular origin, transcriptional profiles of H3F3A K27-mutant and G34-mutant GBM were found to resemble those of distinct anatomical regions at different stages in the developing human brain 40, 137 . Expression of OLIG1 and OLIG2 was originally thought to be a common feature of human gliomas [138] [139] [140] , and OLIG2 was considered to be essential for promoting gliomagenesis in vivo 141, 142 . However, H3F3A G34-mutant GBMs presumably arise from NSCs or undifferentiated progenitor cells (not of oligodendroglial lineage), which epigenetically repress OLIG1 and OLIG2 expression 40 in order to preserve multipotency, in contrast with other glioma subtypes that are initiated from OLIG2-positive progenitor-like cells of the subventricular zone 143 .
Novel strategies in glioblastoma therapy Current postoperative standard treatment for patients with GBM is mainly based on unselective induction of DNA damage via radiotherapy and alkylating agents such as temozolomide 8 . The majority of drugs that specifically target key signalling pathways and mechanisms of gliomagenesis, such as RTK signalling (erlotinib [144] [145] [146] [147] , gefitinib 147, 148 , cetuximab 149 and imatinib [150] [151] [152] [153] ) or angiogenesis (bevacizumab 154, 155 and cediranib 156 ), do not provide a significant survival benefit when tested alone or in combination with other therapies in unselected GBM patient cohorts (reviewed in REF. 157 ). Comparable results were obtained when combining these drugs with pharmacological HDAC inhibitors (such as panobinostat 158 and vorinostat 158, 159 ), although the use of an HDAC inhibitor such as valproic acid in addition to radiotherapy was associated with a better outcome in patients with GBM 160, 161 . However, it should be noted that efforts to identify molecularly defined patient subgroups for targeted therapies have generally been lacking, and it is possible that within the context of a negative clinical trial, subgroups of patients could be defined
Box 2 | In vivo tumour models of glioblastoma
In vivo tumour models provide an indispensable tool that can be used to study the contribution of cancer-related genes or to develop and evaluate novel treatment options. Strategies to reproduce glioblastoma (GBM) tumours in animals include xenograft transplantation models, germline modification of mouse strains and/or somatic gene transfer 192, 193 . Orthotopic injection of primary human GBM cells into immunocompromised mice gives rise to tumours that partially retain histological features and key molecular characteristics of human GBM but that have the disadvantages of an altered tumour immunology and the absence of a natural microenvironment [194] [195] [196] [197] . To recapitulate the diversity of human GBM subgroups 23, 25, 40 , genetically engineered mouse models that facilitate spontaneous tumour growth have been generated by adopting key glioma signature mutations in receptor tyrosine kinase (RTK) genes, TP53, PTEN, RB, neurofibromin 1 (NF1) and in cell cycle pathways 192, 193, 198, 199 . Although the overexpression of either epidermal growth factor receptor (EGFR) or EGFR variant III (EGFRvIII) is insufficient to effectively promote tumour formation from neuroglial precursors 200 or astrocytic cells 200, 201 , GBM that resembles human tumours of the classical transcriptome subtype 25, 40 can be induced by the overexpression of EGFRvIII (and, less efficiently, wild-type EGFR) with concomitant loss of the cyclin-dependent kinase inhibitor 2A (Cdkn2a) and/or both Pten and Trp53 loci [202] [203] [204] [205] . Similarly, platelet-derived growth factor-driven gliomagenesis recapitulates GBM formation in mice when it is combined with germline loss of Cdkn2a, Pten or Trp53 . This model has been successfully used to study paediatric and adult GBM biology 192, 206, 209, 210 and produces GBMs that are similar to the proneural and RTK-I GBM subtypes 23, 25, 40 . The mesenchymal subtype of GBM might be best investigated using established models that are based on loss-of-function of Nf1, which cooperates with early Trp53 mutations (and Pten haploinsufficiency) to induce astrocytomas of different grades 131, [211] [212] [213] [214] [215] . Although molecular profiling of genetically engineered GBM mouse models suggests significant similarities with the adult human disease 199 , it might not show intratumoural heterogeneity to the same degree that occurs in primary tumours, and many novel findings of recent genome-wide studies have not yet been successfully transferred into in vivo models, including recurrent mutations in isocitrate dehydrogenase 1 (IDH1) 216 , H3F3A, HIST1H3B
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, α-thalassaemia/mental retardation syndrome X-linked (ATRX) and others. These are now being assessed in the context of reasonable co-oncogenic alterations to complement the currently available collection of GBM in vivo models.
Warburg effect
A predominant production of energy by a high rate of glycolysis followed by lactic acid fermentation in the cytosol that is observed in most cancer cells in the presence of oxygen.
that would benefit from such a specific therapeutic approach. Indeed, the identification of several different molecular subgroups 25, 27, 40 would provide an argument against the use of one standardized therapy for GBM, and the increasing knowledge about the genetic and/or epigenetic events that drive these subgroups offers the opportunity to design innovative patient-tailored treatment protocols.
Given the high prevalence of IDH mutations in GBM and other malignancies, such as acute myeloid leukaemia (AML), several studies have sought to therapeutically target the neomorphic enzymatic activity of mutant IDH1 and IDH2 using specific inhibitors [162] [163] [164] . The small molecule AGI-5198 was recently shown to inhibit R132H-mutant IDH1, which led to reduced levels of 2-HG and substantially reduced growth of glioma cells in vitro and human glioma xenografts in vivo 162 . Interestingly, pharmacological blockade of mutant IDH1 did not reverse the G-CIMP in glioma xenografts, but it induced the expression of genes that were associated with astrocytic and oligodendrocytic differentiation 162 .
Although not yet tested in GBM, a recent study has reported the successful inhibition of mutant IDH2 by a small molecule (AGI-6780) in AML cells 164 . These encouraging data show that such new drugs might be an effective treatment option for patients with an IDH-mutant GBM.
By contrast, GBMs that lack mutations of IDH1 or IDH2 have recently been shown to use alternative energy resources, such as branched-chain amino acids (BCAAs), to compensate for increased metabolic demand during tumour growth and disease progression. Expression of branched-chain amino acid transaminase 1 (BCAT1) was found to be highly dependent on intracellular levels of 2-OG, which is mainly produced by (wild-type) IDH1 (REF. 165 ). Impaired BCAA metabolism as a result of knockdown of BCAT1 or overexpression of mutant IDH1 resulted in reduced cell proliferation 165 , which renders the reprogramming of energy metabolism an attractive target for innovative therapeutic approaches in GBM. Interestingly, the metabolic enzyme pyruvate kinase M2 (PKM2; also known as PKM) was shown to have a non-metabolic function as a key regulator of histone phosphorylation and acetylation. Activation of EGFR (and PDGFR) results in activation of ERK2, which was found to phosphorylate PKM2 and thereby lead to nuclear translocation and promotion of the Warburg effect 166 . Nuclear PKM2 was found to phosphorylate histone H3 at threonine 11, which caused dissociation of HDAC3 from the CCND1 and MYC gene promoters 167 (FIG. 2) .
Subsequent expression of cyclin D1 and MYC owing to increased acetylation of H3 at lysine 9 was found to induce cell proliferation and gliomagenesis 166 . The identification of histone mutations in a large proportion of HGGs from paediatric and adolescent patients 41, 101 has raised expectations for targeted treatment approaches that tackle these tumours 40, 43 . Although the precise mechanism of K27M-mediated PRC2 inhibition is not fully understood, pharmacological intervention that targets K27M-mutant H3.3 or downstream consequences of this change might represent the ultimate therapeutic goal. However, care must be taken here because the role of the PRC2 complex in oncogenesis seems to be highly context-dependent, and unspecific pharmacological H3K27me3 upregulation in K27M-mutant tumours could in fact promote disease progression, as has been shown for other malignancies that harbour EZH2-activating mutations [168] [169] [170] . ALT has been shown to be the predominant telomere maintenance mechanism in most H3-mutant HGGs (especially in those with G34R or G34V alterations) 41 , so this process might be a promising biological target when developing more powerful drugs in the future, as we begin to understand the underlying molecular details. By contrast, pharmacological inhibition of telomerase activity might be more effective against GBM in adult patients, given the dependence of these GBMs on high levels of telomerase expression 171 (FIG. 3) . Despite the manifold differences between GBM subtypes, the developing overall theme of epigenetic deregulation holds promise for epigenetic modulators to be active across subsets of epigenetically distinct tumours, as has recently been shown for a new class of agents that target the bromodomain and extra terminal (BET) domain proteins 172 .
Despite the identification of these multiple new targets in certain patient subgroups, bridging the gap between identification of recurrent genomic drivers, such as EGFR, and successful targeted therapies remains a considerable challenge, as indicated by the above-mentioned failures of many of the agents that have been tested to date. The development of novel drugs requires accurate assessment of pharmacodynamic and pharmacokinetic parameters of drug activity in preclinical and clinical trials, and penetration of the blood-brain barrier is an additional challenge (although the integrity of this barrier in GBM is debatable). Although some drugs show detectable activity both in vitro and in vivo, downstream signal transducers may remain unaffected 173 , and treated tumours ultimately progress even after administration of drugs that are able to induce a clinical response in patients with GBM. One reason for the failure of early clinical trials could have been a lack of patient selection for a specific therapy, which implies that molecular determinants of the response to a chosen intervention are needed 174 . Another reason could have been preexisting 175 or emerging tumour resistance mechanisms in response to treatment; for example, tumour resistance mechanisms that occurred through activation of alternative RTKs as a result of EGFR inhibition 176 . Owing to the intertumoural and intratumoural molecular heterogeneity of GBM, it is likely that only a small proportion of patients will benefit from therapeutic interventions that are aimed at any one target, but synergistic combination approaches might prove more effective [177] [178] [179] . This likelihood highlights the need for prospective tissue collection in order to maximize the information that is gained from clinical trials. Molecular pathological stratification criteria are needed in GBM and other cancers to optimize enrolment in the therapeutic arm that is most adapted to tumour biology, and the efficacy of a specific agent should be considered in the context of known and clinically relevant biological subsets of glioma.
Summary Recent large-scale profiling studies have revealed a wealth of novel findings that have changed the way we look at the genomic and epigenomic landscape of GBM. The community is slowly gaining insight into the complex interactions between genetic alterations and changes in DNA methylation, histone modifications, chromatin remodelling and gene expression, and is beginning to understand how deregulation on different levels might contribute to the pathogenesis of GBM. IDH and H3-mutated GBM are outstanding examples whereby disrupted epigenetic mechanisms due to genetic mutations result in the formation of mutation-specific epigenetic and transcriptional programmes. These and other recurrent genetic aberrations occur in a specific context of cellular origin, co-oncogenic hits and epigenetic phenomena, and are present in distinct patient populations. The biological distinction of GBM subgroups should therefore guide the design of future clinical trials. In addition, the complex interplay of 'hard-wired' genetic events and potentially reversible alterations of the GBM epigenome offers novel opportunities for the development of molecularly targeted therapies, which might represent a promising strategy to tackle this deadly brain tumour. 
